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PAspirin Plus Clopidogrel Therapy
Increases Early Venous Graft Patency
After Coronary Artery Bypass Surgery
A Single-Center, Randomized, Controlled Trial
Ge Gao, MD,* Zhe Zheng, MD,* Yi Pi, MD,* Bin Lu, MD,† Jinguo Lu, MD,† Shengshou Hu, MD*
Beijing, The People’s Republic of China
Objectives We sought to evaluate the effect of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft occlu-
sion at 3 months after coronary artery bypass grafting (CABG).
Background Prevalence of graft occlusion is high after CABG. Aggressive antiplatelet therapy is expected to improve early
post-operative graft patency.
Methods From December 2007 through December 2008, 249 consecutive patients undergoing elective CABG at Fuwai
Hospital were randomly assigned to 2 groups: 124 received aspirin (100 mg) plus clopidogrel (75 mg) daily (AC
group), and 125 received aspirin (100 mg) alone daily (A group). Antiplatelet therapies were initiated when post-
operative chest tube drainage was 30 cc/h for 2 h. All participants were invited for clinical follow-up and 64-
slice multislice computed tomography angiography (MSCTA) analysis at 3 months post-operatively. Generalized
estimating equations analysis was used to determine predictors of graft patency.
Results One participant, from group A, died before 3-month follow-up. Of the remaining 248 patients, 224 (90.3%) un-
derwent MSCTA. Participants had similar pre-operative and intraoperative characteristics at baseline. No signifi-
cant differences were observed in intraoperative transit-time flow measurement findings or major adverse
cardiac-related events. Three-month MSCTA follow-up revealed that saphenous vein graft patency was 91.6%
(219 of 239) in the AC group versus 85.7% (198 of 231) in the A group (p  0.043). In multivariate analysis,
combined antiplatelet therapy independently increased venous graft patency (p  0.045).
Conclusions Aspirin plus clopidogrel is more effective in venous graft patency than aspirin alone in the short term after
CABG, but further, long-term study is needed. (The Clopidogrel and Aspirin After Surgery for Coronary Artery
Disease; NCT00776477) (J Am Coll Cardiol 2010;56:1639–43) © 2010 by the American College of Cardi-
ology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.104C
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there is a high prevalence of venous graft closure within 3
onths after coronary artery bypass grafting (CABG) sur-
ery (1). The main mechanism at this stage is graft
hrombosis, which sets the stage for graft stenosis and
cclusion. Despite its established comprehensive clinical use
nd benefit in patients with coronary heart disease, aspirin
herapy has limitations, including failure to arouse a com-
lete antiplatelet response in 5% to 10% of patients (2).
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010, accepted March 18, 2010.lopidogrel is a promising antiplatelet agent; its clinical
fficacy at reducing ischemic events and mortality in patients
ith coronary and vascular disease has been demonstrated in
everal large clinical trials (3,4). To date, however, no trial
as prospectively evaluated the synergistic effects of aspirin
lus clopidogrel on saphenous vein graft (SVG) disease after
ABG. Therefore, we conducted a randomized controlled
rial comparing aspirin plus clopidogrel with aspirin alone in
ABG patients revascularized with at least 1 saphenous vein.
he aim of this study was to evaluate the effect of combined
ntiplatelet therapy 3 months after CABG on SVG patency
nd also the major adverse cardiac-related events.
ethods
atients. The study was a prospective randomized con-
rolled trial. All patients referred for isolated surgical coronary
evascularization from December 2007 to December 2008
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Hospital were screened accord-
ing to the inclusion criteria. This
study was approved by the local
ethical committee with patient
informed consent.
Inclusion criteria. Patients under-
going primary isolated CABG,
with or without cardiopulmonary
bypass, were eligible for inclusion
in the study.
Exclusion criteria. Patients with
n abnormal quantity of platelets before operation (100 
09/l or 300  109/l); previous CABG or other cardiac
urgery; need for concomitant valve surgery or aneurysm
esection; serum creatinine 130 mol/l; left ventricular
jection fraction 30% on pre-operative ultrasound; liver
isease; clopidogrel or aspirin intake within 7 days of
peration; need for perioperative warfarin; active gastrodu-
denal ulcer or post-operative gastrointestinal bleeding;
rofuse post-operative pleural effusion (drainage200 ml/h
or 2 h or more); need for secondary thoracotomy to stop
leeding for cardiac tamponade; postoperative low cardiac
utput syndrome or requirement for high levels of hemo-
Figure 1 Flow Chart of the Study
Flow chart of the study, including deaths, numbers, and reasons for loss to
follow-up and numbers contributing to analyses. GroupA  aspirin alone group;
GroupAC  aspirin plus clopidogrel group; MACE  major adverse cardiac-
related events; MSCTA  multislice computed tomography angiography.
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
MACE  major adverse
cardiac events
MSCTA  multislice
computed tomography
angiography
SVG  saphenous vein
grafttynamic support (more than 2 inotropes for more than 24 h
nd/or intra-aortic balloon pump); and clinical instability,
uch as perioperative myocardial infarction or malignant
umor, were excluded from the study.
ample size. According to previous studies, single-aspirin
rotocol has a venous graft occlusion rate of 15% 3 months
fter surgery. As for dual antiplatelet protocol, the rate is
0%. We found that a 5% difference between 2 arms can be
eliably detected under a power of 80%, if we have 270
enous grafts in each arm (significance level  0.05).
urgical procedures. All patients underwent either off-
ump or on-pump CABG, according to surgeon discretion
n the basis of anatomic and clinical findings. Before chest
losure, mean flow values and pulsatile index were obtained
ith transit-time flow measurement (Medi-stim Butterfly
owmeter, Medi-stim AS, Oslo, Norway). If mean flow
alues were 10 ml/min, pulsatile index was 5.0, or any
ossible graft kinking or compression needed to be detected,
he anastomosis was redone. Patients were excluded from
he study if remeasurement results remained unsatisfactory.
dministration of antiplatelet agents. Patients with suc-
essful CABG surgery were randomly assigned to 2 groups:
roup A, receiving aspirin 100 mg daily; group AC, receiv-
ng aspirin 100 mg plus clopidogrel 75 mg daily. Antiplate-
et agents were given orally when clinical stability was
nsured and chest tube output was30 ml/h for at least 2 h.
oth antiplatelet therapies should be administered within
8 h. All patients received antiplatelet therapy for 3 months
fter operation.
rimary and secondary end point. The primary objective
as to determine the effect of dual antiplatelet therapy on
he incidence of graft occlusion at 3 months after bypass
urgery, as assessed by multislice computed tomography
ngiography (MSCTA). A secondary objective was to assess
re-Operative Clinical Characteristicsf the A nd A GroupsTable 1 Pre-Operative Clinical Characteristicsof the A and AC Groups
Characteristic
A Group
(n  111)
AC Group
(n  113) p Value
Age (yrs) 59.8 7.92 57.9 8.25 0.096
Female 18 (16.2) 20 (17.7) 0.767
BMI (kg/m2) 25.4 3.60 25.9 2.69 0.195
Hypertension 63 (56.8) 70 (61.9) 0.429
Diabetes 45 (40.5) 45 (39.8) 0.913
Hyperlipidemia 44 (39.6) 40 (35.4) 0.512
History of smoking 66 (59.5) 59 (52.2) 0.275
CHD family history 16 (14.4) 14 (12.4) 0.656
Previous PCI 18 (16.2) 12 (10.6) 0.219
Previous MI 49 (44.1) 56 (49.6) 0.417
Previous CVA 8 (7.2) 3 (2.7) 0.115
Pre-operative LVEF (%) 59.83 7.87 60.64 7.71 0.502
OPCAB 59 (53.2) 72 (63.7) 0.109
alues are mean  SD or n (%).
A aspirin alone; AC aspirin plus clopidogrel; BMI body mass index; CHD coronary heart
isease; CVA cerebrovascular accident; LVEF left ventricular ejection fraction; MImyocardial
nfarction; OPCAB  off-pump coronary artery bypass grafting; PCI  percutaneous coronary
ntervention.he effect of treatment on the occurrence of major adverse
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November 9, 2010:1639–43 Aspirin Plus Clopidogrel for Venous Graft Patencyardiac events (MACE), defined as follows: 1) cardiogenic
eath; 2) myocardial infarction (hospital visit for myocardial
nfarction reported by patient or hospital admission for
yocardial infarction reported by cardiologist); and 3) the
eed for revascularization (repeat operation or angioplasty
eported by patient or cardiologist) through 3 months after
ABG.
raft patency by 64-slice MSCTA. All patients were
cheduled for a systematic MSCTA at 3 months after
urgery with the 64-slice MSCTA scanner (GE Healthcare,
ilwaukee, Wisconsin). The images were transferred to a
tand-alone workstation (Deep Blue, ADW4.3, GE
ealthcare) and evaluated with dedicated analysis software.
he results of MSCTA were independently reviewed by 2
adiologists blinded to randomized allocation. Each graft
as classified as patent (flow visible), occluded, or not
nalyzable (e.g., because the graft was obscured by a metal
igature clip or because the image quality was poor). When
conduit did not fill with contrast at all, it was considered
ccluded and was included with string sign found in any
egment (including proximal anastomotic site, distal anas-
raft Characteristics of PatientsTable 2 Graft Characteristics of Patients
Parameters
Group A
(n  111)
Group AC
(n  113) p Value
Distal anastomosis (n) 416 427
LAD 110 112 NS
Diagonal 56 61 NS
LCx system 131 133 NS
RCA system 119 121 NS
Per person 3.75 (416/111) 3.78 (427/113) NS
Graft type (n) 345 359
LIMA 109 112 NS
RA 3 5 NS
SVG 233 242 NS
Sequential bypass 70 68 NS
Number of grafts (n) 111 113
2 6 5 NS
3 87 83 NS
4 18 25 NS
Grafts/patients 3.11 (345/111) 3.18 (359/113) NS
 aspirin alone; AC  aspirin plus clopidogrel; DA  diagonal artery; LAD  left anterior
escending coronary artery; LCx  left circumflex coronary artery; LIMA  left internal mammary
rtery; RA  radial artery; RCA  right coronary artery; SVG  saphenous vein graft.
ean Graft Flow and Pulsation Index by Intraoperative TTFM in A aTable 3 Mean Graft Flow and Pulsation Index by Intraoperative
Graft Position
Graft Number
Graft Flow (m
A
Group
AC
Group
A Group
25th, 50th, 75th
Percentiles
AC
25th, 5
Perc
LIMA: anterior wall 109 112 21, 32, 33.5 18.5, 29
Aorta: anterior wall 26 30 22, 34, 37 20, 29,
Aorta: lateral wall 97 102 30, 39, 49.5 27.75, 3
Aorta: inferior wall 110 110 24, 37.5, 49.25 24, 36.5TFM  transit-time flow measurement; other abbreviations as in Tables 1 and 2.omotic site, and main trunk). Both of these latter findings
ere considered together and referred to as occlusion in the
nalysis. Discrepancies in patency definition were reviewed
y a third investigator and resolved by consensus.
tatistical analysis. Clinical baseline characteristics and
ost-operative outcomes were compared statistically. The
tudent t test and chi-square test were used to analyze
ontinuous and categorical variables, respectively. A non-
arametric test was used to compare graft flow and pulsation
ndexes of the 2 groups. In univariate analyses, means and
Ds were used for continuous variables, and frequencies and
ercentages were used for categorical variables. Multivari-
ble generalized estimating equations analysis was used to
xamine independent risk factors related to vein graft
atency. In all cases, a p value 0.05 was considered as
tatistically significant. All analyses were performed with
PSS statistical software version 11.0 (SPSS, Inc., Chicago,
llinois).
esults
wo-hundred forty-nine cardiac surgery candidates were
andomized to group A (n  125) or group AC (n  124).
f the 249 participants, 1 (0.4%) (from group A) died at 6
eeks after CABG surgery. Of the remaining 248 patients,
39 (96.4%) completed a 3-month follow-up, and 224
90.3%) underwent MSCTA. Deaths, numbers and reasons
or loss to follow-up, and numbers contributing to analyses
re shown in Figure 1. The patient demographic, disease
ntity, and comorbidity data were collected prospectively
nd are summarized in Table 1. Participants had character-
stics at baseline similar to the entire randomized cohort. No
ignificant difference was found between the 2 groups in
erms of MACE. Graft characteristics including number of
istal anastomosis at different sites, number of different graft
ypes, number of grafts and grafts/patients were compared;
o significant difference was found (Table 2). Intraoperative
ransit-time flow measurement findings were also similar in
oth groups (Table 3).
At 3-month MSCTA follow-up, patency was studied in
04 grafts of 224 patients; 11 (1.6%) grafts were deemed
ondiagnostic by 2 radiologists. Overall, 58 (8.4%) of 693
rafts were classified as occluded after disagreements were
econciled—23 (6.5%) in the AC group versus 35 (10.3%)
C Groupsin A and AC Groups
Pulsation Index
5th
p Value
A Group
25th, 50th, 75th
Percentiles
AC Group
25th, 50th, 75th
Percentiles p Value
5 0.054 1.7, 2.0, 2.2 1.625, 2.15, 2.375 0.176
0.256 1.5, 1.9, 2.2 1.85, 2.0, 2.175 0.261
0 0.573 1.5, 1.9, 2.1 1.6, 1.9, 2.2 0.577
0.702 1.4, 2.0, 2.5 1.4, 1.9, 2.125 0.153nd ATTFM
l/min)
Group
0th, 7
entiles
, 32.7
31.75
9.5, 5
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Aspirin Plus Clopidogrel for Venous Graft Patency November 9, 2010:1639–43n the A group. Graft patency for SVGs was 91.6% (219
f 239) in the AC group versus 85.7% (198 of 231) in the
group (relative risk: 1.707; 95% confidence interval:
.010 to 2.886; p  0.043) (Table 4). In the multivariate
nalysis, combined antiplatelet therapy independently
ncreased venous graft patency (relative risk: 1.996; 95%
onfidence interval: 1.015 to 3.922; p  0.045). Other
trong predictors of higher venous graft patency rate were
arger distal runoff, higher mean graft flow, and lower
ulsatile index (Table 5).
Prevalence of Graft Occlusion in A and AC GrouTable 4 Prevalence of Graft Occlusion in A
Type
A Group
Total/Evaluable Occluded n (%) Total/Eva
LIMA 109/106 1 (0.9) 112/1
RA 3/3 1 (33.3) 5/4
SVG 233/231 33 (14.3) 242/2
Total 345/340 35 (10.3) 359/3
CI  confidence interval; other abbreviations as in Tables 1 and 2.
ultivariate Analysis of Relative Risk Factorsor Venous Graft Patency at 3 Months After CABGTable 5 Multiv riate An lysis of Rela ive Risk Factorsfor Venous Graft Patency at 3 Months After CABG
Risk Factor Odds Ratio 95% CI p Value
Sex
Male Reference
Female 0.6 0.187–1.921 0.390
Hyperlipidemia
Yes Reference
No 1.096 0.511–2.353 0.814
Diabetes
Yes Reference
No 0.729 0.375–1.418 0.352
History of smoking
Yes Reference
No 1.032 0.420–2.540 0.945
Antiplatelet therapy
Aspirin alone Reference
Aspirin  clopidogrel 1.996 1.015–3.922 0.045
Anastomotic position of SVG
RCA Reference
LCx 1.505 0.683–3.316 0.311
LAD 0.836 0.293–2.382 0.737
Sequential anastomosis
Yes Reference
No 1.092 0.423–2.817 0.856
CABG procedure
On-pump Reference
Off-pump 1.076 0.509–2.275 0.849
Age 1.026 0.985–1.069 0.213
BMI 1.038 0.942–1.143 0.452
Mean graft flow 1.045 1.005–1.088 0.029
Pulsation index 0.438 0.309–0.622 0.001
Runoff 24.159 3.685–158.395 0.001
Proximal stenosis of target vessels 6.104 0.191–195.495 0.306iABG  coronary artery bypass grafting; other abbreviations as in Tables 1 and 2.iscussion
he primary reason for graft stenosis and occlusion after
ABG is formation of thrombus, which is related to
nastomotic technique, graft quality, and coagulation
unction in the perioperative period (5). Platelets play a
undamental role in this process. Even with standard
spirin therapy, a significant proportion of patients
resent post-operatively with graft stenosis or occlusion,
specially with vein material, and seem to be at increased
isk for developing adverse vascular events (6). Many
eople are affected by aspirin resistance, defined as unde-
ectable platelet inhibition after 1 week of therapy (7).
lopidogrel is a thienopyridine antiplatelet agent that in-
ibits adenosine diphosphate-dependent platelet activation
nd aggregation, unlike aspirin, which mainly selectively
epresses platelet cycloxygenase-1 and interrupts the forma-
ion of thromboxane A2. They work on different stages of
hrombosis, and therefore theoretically the combination of
spirin and clopidogrel should lead to superior potent
ynergistic antithrombotic effects compared with either
herapy alone (8).
The benefit of aspirin plus clopidogrel on the outcome of
ABG has been demonstrated in several trials (3,9,10);
hether the combination of aspirin and clopidogrel is
uperior to aspirin alone on graft patency is not yet resolved.
ur study is the first randomized controlled trial to examine
raft patency as the primary end point, providing definitive
linical data on the efficacy of combined antiplatelet therapy
n SVG patency. The result of generalized estimating
quation analysis demonstrates that SVG patency is affected
y multiple patient-specific and procedure-specific features,
nd use of dual antiplatelet therapy is only 1 such factor.
he positive aspect of this study is the exploration of an
deal antiplatelet protocol that can significantly improve
enous graft patency.
tudy limitations. It is important to remember that the
urrent trials were carried out in a single center without
lacebo control, which is the main limitation of this study.
n addition to the MSCTA observers, the investigator and
atients were not blinded to the randomized allocation.
owever, the objective results of MSCTA would be hardly
mpaired by this shortcoming. Furthermore, we did not
valuate platelet function; consequently, individual variabil-
C Groups
Group
p Value
Relative Risk
(95% CI)Occluded n (%)
2 (1.8) 0.583 0.519 (0.048–5.638)
1 (25) 0.809 1.333 (0.129–13.743)
20 (8.4) 0.043 1.707 (1.010–2.886)
23 (6.5) 0.073 1.580 (0.954–2.617)psand A
AC
luable
10
39
53ty in the antiplatelet therapy was not taken into account. In
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November 9, 2010:1639–43 Aspirin Plus Clopidogrel for Venous Graft Patencyhe current study, there was no significant difference be-
ween the 2 groups on the end points of MACE, most
robably due to our relatively small sample size and short
ollow-up period. Longer follow-up and larger sample size
ight be warranted to reveal the effectiveness of dual
ntiplatelet therapy on the end point of clinical outcome.
onclusions
his study shows that the combination of aspirin plus
lopidogrel significantly increased venous graft patency at 3
onths after CABG compared with aspirin alone. Com-
ined antiplatelet therapy, larger runoff, and higher mean
raft flow are independently correlated with elevated venous
raft patency, whereas pulsatile index is an independent risk
redictor. No significant differences in MACE between the
groups were observed.
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